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CPXV12 is the first poxvirus gene product demonstrated to inhibit the transporter associated with antigen
processing (TAP). This cowpox virus function acts in concert with a second gene product, CPXV203, to effi-
ciently suppress MHC class I antigen presentation and enhance in vivo virulence.2010 marks the 30th anniversary of the
global eradication of smallpox, a remark-
able achievement that began on May
14th, 1796, when Edward Jenner (Figure 1)
inoculated James Phipps with live cow-
pox virus from the hand of a milkmaid,
Sarah Nelmes, and subsequently showed
the boy to be immune to smallpox. This
experiment not only laid the foundation
for the global eradication of smallpox,
but also established vaccination (Latin
vacca, for cow) as a means of generating
a protective immune response. The pro-
tective immunity elicited by orthopoxvi-
ruses is thought to involve both humoral
and cellular components of the adaptive
immune system (Dasgupta et al., 2007).
Two papers in this issue of Cell Host &
Microbe now identify a second cowpox
virus (CPXV) gene product that downre-
gulates major histocompatibility complex
class I (MHC class I) molecules and con-
founds the adaptive cellular immune
response (Alzhanova et al., 2009; Byun
et al., 2009).
Downregulation of MHC class I was first
identified in adenovirus (E3-19K) and is
now recognized as a major immune strat-
egy for many viruses, including HIV (Han-
sen and Bouvier, 2009). Decreased cellsurface MHC class I expression will pre-
vent specific viral peptides from being
presented to cytotoxic T lymphocytes
(CTLs) and therefore promote immune
evasion. In recent years, the field has
been dominated by studies on herpesvi-
ruses. An impressive array of herpesviral
gene products target multiple stages in
the MHC class I antigen presentation
pathway, including peptide generation
by proteasomes, TAP-mediated transport
of peptides into the ER, and the retention
or ER-associated degradation of newly
synthesized MHC class I heavy chain.
Once formed, the heterotrimeric complex
of MHC class I heavy chain, b2-microglo-
bulin, and peptide traffics to the cell
surface, but may yet be arrested in the
secretory pathway or removed from the
cell surface by ubiquitination and endo-
cytosis.
Interest is now growing in the capacity
of poxviruses to actively evade the cellular
immune response (Guerin et al., 2002;
Campbell et al., 2007; Hammarlund et al.,
2008). The research group headed by
Klaus Fru¨h first demonstrated that CPXV
inhibits MHC class I trafficking, while
Wayne Yokoyama’s laboratory identified
the CPXV203 gene product as respon-Cell Host & Microbe 6,sible for ER retention of newly synthesized
MHC class I. However, when CPXV203
was deleted from the virus, it was clear
that CPXV encoded a second MHC class
I evasion function capable of acting
independently. Both groups now identify
this second function to be encoded by
CPXV12 and, in complementary studies,
go on to investigate its mechanism of
action and role in evading CD8+ cytotoxic
T cells (Figure 1).
The two groups came to CPXV12 from
opposite directions. Yokoyama’s group
performed a series of iterative deletions
in the CPXV genome to ultimately map
the gene by loss-of-function in the virus
(Byun et al., 2009), whereas Fru¨h’s group
interrogated a panel of potential candi-
dates in transient gain-of-function assays
(Alzhanova et al., 2009). In the prototype
BR strain, CPXV12 encodes a 69 amino
acid (8.5 kDa) type II membrane protein
that localizes to the ER. In vitro expression
studies using microsomal extracts are
consistent with the protein consisting of
an N-terminal membrane-spanning region
with the C terminus extruding into the
lumen of the ER (Alzhanova et al., 2009).
To get a handle on CPXV12, the protein
was expressed with an epitope tag andNovember 19, 2009 ª2009 Elsevier Inc. 395
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tate in a complex with TAP1,
tapasin, and mouse class I
heavy chain. MHC class I
was synthesized at the same
rate in the presence of
CPXV12 yet was unable to
dissociate from the peptide-
loading complex and failed
to mature. This effect could
be reversed by the addition
of exogenous matched MHC
class I-binding peptide. The
data were consistent with a
model in which the CPXV12
gene product was binding
directly to the MHC class I-
associated loading complex
to restrict access to peptide
(Byun et al., 2009).
Alzhanova and coworkers
also observed exogenous
peptide-stabilized de novo-
synthesized MHC class I and
performed a direct test of
TAP function. When synthetic
peptide containing a glyco-
sylation site is artificially
loaded into cells, the TAP-
transported fraction is glyco-
sylated on entry to the ER.
CPXV12 inhibited peptide
glycosylation and was
accordingly classified as an
inhibitor of TAP function.
Comparing the two reports,
CPXV12-mediated TAP inhi-
bition appears more effective
in human than in murine cells. Two of the
best-characterized TAP inhibitors from
herpesviruses, the HSV-encoded ICP47
and HCMV-encoded US6, are species-
specific and differ mechanistically in their
TAP inhibition. While ICP47 binds the
cytosolic face of TAP and inhibits peptide
binding and ATP hydrolysis (Gorbulev
et al., 2001), US6 binds the transporter
from the lumenal side to prevent the
binding and hydrolysis of ATP (Hewitt
et al., 2001). Further studies are required
to fully define which component of the
peptide-loading complex is the molecular
target of CPXV12, how CPXV12 prevents
TAP-mediated peptide translocation, and
whether host species differences account
for the differences in TAP inhibition.
Although named after its overt associa-
tion with cows, the virus is endemic in
European rodents,withoccasional reports
in cats, man, and other species. With the
decline in smallpox vaccination coverage,
the incidence of CPXV zoonotic events is
expected to increase. Importantly, the
two cowpox evasion genes CPXV12 and
CPXV203 work in combination to protect
infected cells from MHC class I-restricted
CTL recognition in both human and murine
cell systems. The extended host range of
CPXV may explain the requirement for
both CPXV12 and CPXV203 to efficiently
suppress MHC class I in mouse, man,
and presumably other species, a charac-
teristic not usually associated with other
viral MHC class I inhibitors.
The fact that rodents are natural hosts
for CPXV enhances the validity of the
in vitro and in vivo murine studies. Dele-
tion of either CPXV12 or CPXV203 alone
had a modest effect on MHC class I
expression (in both mouse and human
cells), but in viruses deleted
of both CPXV12 and
CPXV203, the effect was
dramatic. Furthermore, func-
tional assays showed that
T cells from mice infected
with CPXV were activated
much more efficiently in vitro
by cells infected with the
double-deletion mutant virus
than by cells infected with
single mutants or wild-type
CPXV. Since, in mice infected
with wild-type CPXV, infec-
tion induced an efficient
T cell response, the evasion
function appears potent with
respect to recognition rather
than priming, suggesting that
cross-priming may also be
operating in this system (Byun
et al., 2009; Dasgupta et al.,
2007).
Fru¨h’s laboratory used both
human and murine T cells
raised to vaccinia virus
(VACV), cleverly taking advan-
tage of the cross-reactivity of
orthopoxvirus-specific CTLs
that was so effectively ex-
ploited by Jenner. The reader
needs to be aware that while
CPXV and VACV are antigeni-
cally related orthopoxviruses,
they are distinct. Although it
is accepted that Jenner used
CPXV, at some point (lost in
time) VACV replaced CPXV
as the smallpox vaccination agent. VACV
is most closely related to camelpox, but
its source remains unknown. VACV-
specific T cells were efficiently activated
in vitro by cells infected with wild-type
VACV as well as with the CPXV double-
deletion mutant (CPXVD12D203), but
only weakly by cells infected with either
CPXV single mutants or the parental virus.
In combination, CPXV12 and CPXV203
therefore provide efficient protection
against T cells in the context of virus infec-
tion in vitro. The vulnerability of VACV-in-
fected cells to T cell recognition supports
in vitro evidence that this virus does not
encode a specific mechanism to subvert
MHC class I antigen presentation.
The in vitro demonstration of the
potency of CPXV12 and CPXV203 in pro-
tecting against CD8+ T cells was further
consolidated in the in vivo murine model,
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Figure 1. Cowpox Inhibits MHC Class I Antigen Processing
CPXV12 acts as a TAP inhibitor to prevent peptide loading onto MHC class I in
the ER. The CPXV203 protein contains an ER-retention signal that is instru-
mental in promoting retrieval and recycling of MHC class I from the Golgi.
A portrait of Edward Jenner is shown above the model.396 Cell Host & Microbe 6, November 19, 2009 ª2009 Elsevier Inc.
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deletion mutant virus correlated with
reduced virus load ten days after infection
and in long-term survival (Byun et al.,
2009). Moreover, the protective effect
was suppressed by depletion of CD8+
T cells (Byun et al., 2009). This synergistic
contribution of CPXV12 and CPXV203 to
in vivo virulence clearly demonstrates
that T cells can play an important role in
host defense against poxvirus infection.
It is therefore somewhat surprising that
CPXV12’s function as a TAP inhibitor is
restricted to a single poxvirus species
and that even within the species CPXV,
it is not ubiquitous. The CPXV12 homo-
logs in strains GRI and GER-91 are highly
conserved through their transmembrane
domain, but diverge in their C-terminal
ER lumenal elements. The Fru¨h laboratory
speculates that the larger protein in strain
GER-91 has properties compatible with it
being an NK cell-inhibitory receptor.
The capacity of CPXV12 and CPXV203
together to promote virulence is impres-
sive, particularly when compared to similar
experiments performed with murine
cytomegalovirus (MCMV). Despite theHow Aging Comp
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between proinflammatory and anti
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The elderly are more susceptible to path-
ogens, in particular to viral infections.
Influenza or respiratory syncytial virus
(RSV) infections lead to higher mortality
in old people (Thompson et al., 2003).
RSV infection causes approximately
10,000 and influenza A 37,000 yearlywell-documented role of CD8 T cells
in eliciting protection against MCMV,
deletion of three genes implicated in sup-
pressing antigen presentation to CD8+
T cells had only a modest effect on viru-
lence in vivo (Gold et al., 2004). Therefore,
CPXV provides a powerful and physiolog-
ically relevant model system to study the
in vivo role of virus-induced MHC class I
downregulation.
Perhaps the irony for the unsuspecting
Jenner was that his vaccine strategy will
have induced the generation of cross-
reactive CTLs that were fortuitously
more effective against the smallpox target
than against the inoculating agent—
something we struggle to achieve with
vaccination today.
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